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Abstract
Background: The chemokine CCL2 (also known as monocyte chemoattractant protein-1, or MCP-1) is upregulated
in patients and rodent models of traumatic brain injury (TBI), contributing to post-traumatic neuroinflammation and
degeneration by directing the infiltration of blood-derived macrophages into the injured brain. Our laboratory has
previously reported that Ccl2-/- mice show reduced macrophage accumulation and tissue damage, corresponding
to improved motor recovery, following experimental TBI. Surprisingly, Ccl2-deficient mice also exhibited delayed
but exacerbated secretion of key proinflammatory cytokines in the injured cortex. Thus we sought to further
characterise CCL2’s potential ability to modulate immunoactivation of astrocytes in vitro.
Methods: Primary astrocytes were isolated from neonatal wild-type and Ccl2-deficient mice. Established astrocyte
cultures were stimulated with various concentrations of lipopolysaccharide (LPS) and interleukin (IL)-1b for up to
24 hours. Separate experiments involved pre-incubation with mouse recombinant (r)CCL2 prior to IL-1b stimulation
in wild-type cells. Following stimulation, cytokine secretion was measured in culture supernatant by immunoassays,
whilst cytokine gene expression was quantified by real-time reverse transcriptase polymerase chain reaction.
Results: LPS (0.1-100 μg/ml; 8 h) induced the significantly greater secretion of five key cytokines and chemokines
in Ccl2-/- astrocytes compared to wild-type cells. Consistently, IL-6 mRNA levels were 2-fold higher in Ccl2-deficient
cells. IL-1b (10 and 50 ng/ml; 2-24 h) also resulted in exacerbated IL-6 production from Ccl2-/- cultures. Despite
this, treatment of wild-type cultures with rCCL2 alone (50-500 ng/ml) did not induce cytokine/chemokine
production by astrocytes. However, pre-incubation of wild-type astrocytes with rCCL2 (250 ng/ml, 12 h) prior to
stimulation with IL-1b (10 ng/ml, 8 h) significantly reduced IL-6 protein and gene expression.
Conclusions: Our data indicate that astrocytes are likely responsible for the exacerbated cytokine response seen
in vivo post-injury in the absence of CCL2. Furthermore, evidence that CCL2 inhibits cytokine production by
astrocytes following IL-1b stimulation, suggests a novel, immunomodulatory role for this chemokine in acute
neuroinflammation. Further investigation is required to determine the physiological relevance of this phenomenon,
which may have implications for therapeutics targeting CCL2-mediated leukocyte infiltration following TBI.
Background
Cerebral inflammation involving the release of soluble
mediators, infiltration of peripheral immune cells and
activation of resident glial cells, is one of the key patho-
physiological processes contributing to secondary degen-
eration following focal traumatic brain injury (TBI). The
chemokine CCL2 (also known as macrophage chemoat-
tractant protein-1, or MCP-1) is well recognised for its
potent ability to mediate macrophage recruitment and
migration to sites of inflammation [1,2]. In the brain,
CCL2 production is rapidly induced by a range of diverse
inflammatory conditions, and is associated with the infil-
tration of blood-derived macrophages and activation of
microglia [3,4]. Transgenic mice over-expressing Ccl2 in
the central nervous system (CNS) exhibit a robust accu-
mulation of macrophages in the brain [5,6], whereas mice
deficient in the Ccl2 gene show reduced leukocyte infil-
tration after TBI, spinal cord injury and stroke [7-9].
Detection of elevated CCL2 in the serum and cerebrosp-
inal fluid of severe TBI patients [9,10] corroborates a
central role for this chemokine in post-traumatic
neuroinflammation.
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any medium, provided the original work is properly cited.We recently identified an altered profile of cortical cyto-
kine production in Ccl2-deficient mice subjected to a
closed head injury model of focal TBI. Peak levels of inter-
leukin (IL)-1a,I L - 1 b, IL-6, granulocyte-colony stimulating
factor (G-CSF), IL-12(p40), CCL3 and CXCL1 were
delayed and significantly exacerbated in Ccl2-/- mice com-
pared to wild-type mice acutely post-injury, whilst the pro-
duction of other inflammatory mediators including CCL5,
interferon-gamma (IFNg) and IL-2 had reduced produc-
tion in chemokine-deficient animals [9]. These findings
appear paradoxical to the delayed neuroprotection shown
in Ccl2-/- mice, which had reduced macrophage accumu-
lation and tissue damage associated with improved func-
tional recovery over 4 weeks post-injury. We hypothesise
that the altered cytokine network in the brains of Ccl2-/-
mice after injury may indicate a previously unrecognised
role for CCL2 as a modulator of acute CNS inflammation.
Based on astrocytes being the main source of chemokines
including CCL2 [11-14], it is conceivable that CCL2 may
exert immunomodulatory effects on this cell type.
In the current study, we aimed to elucidate whether
CCL2 regulates immune processes by investigating cyto-
kine production from Ccl2-/- astrocytes compared to
wild-type cells in response to inflammatory stimuli
in vitro. We demonstrate that primary Ccl2-/- astrocyte
cultures secrete exacerbated levels of chemokines and
cytokines such as interleukin (IL)-6 compared to wild-
type cells in response to lipopolysaccharide (LPS) and
IL-1b stimulation. Furthermore, production of IL-6
induced by IL-1b in wild-type astrocytes was suppressed
by prior incubation with exogenous CCL2. These results
indicate a likely immunomodulatory role for CCL2 in
astrocytic cytokine production. In combination with other
recently identified functions of this chemokine in neuro-
transmission [15,16] and neuronal cell survival [17-19],
these findings indicate that future application of therapeu-
tics targeting CCL2-mediated leukocyte infiltration follow-
ing TBI may have tangential effects in the injured brain.
Methods
Animals and reagents
The experimental procedure was approved by the Alfred
Medical Research and Education Precinct (AMREP)
Animal Centre, Melbourne, Australia. Ccl2-/- mice
(B6.129S4-Ccl2tm1Rol/J) on a C57Bl/6 background were
obtained from Jackson Laboratory (Maine, USA) and a
breeding colony established at AMREP. C57Bl/6 mice
were used as wild-type controls. Unless otherwise stated,
all reagents were obtained from Invitrogen Laboratories,
Carlsbad, CA or Sigma Aldrich, St Louis, MO.
Isolation of primary mouse astrocytes
Primary astrocyte cultures were obtained from newborn
(0-2 day old) mice as previously described [20,21].
Following isolation of cortices and removal of the
meninges, dissociated cells were suspended in Dulbec-
co’s Modified Eagle’s Media (DMEM) containing 10%
fetal bovine serum (FBS) and 0.25% gentamycin, and
plated on 75 cm
2 flasks pre-coated with 0.1 mg/ml poly-
L-lysine. Cultures were maintained for 7 days to gener-
ate a confluent glial culture.
Prior to trypsinisation, contaminating microglial cells
were separated by vigorous mechanical agitation and
removed by subsequent washing in Hank’s Balanced Salt
Solution (HBSS). Astrocytic monolayers were then dis-
lodged from flasks by trypsinisation (0.25% trypsin in
HBSS and 1 mM EDTA). Cells were seeded in either
24-well plates (1 × 10
5 cells/well) or 75 cm
2 flasks (5 ×
10
5 cells/flask) and grown for 7-9 days until confluent
prior to stimulation. Culture purity was determined by
double-labelling immunohistochemistry for GFAP
(1:1000; DAKO, Glostrup, Denmark) and CD11b (1:150;
BD Pharminogen, San Diego, CA) to identify astrocytes
(>95%) and microglia (<5%), respectively. The lack of
Ccl2 mRNA amplified by quantitative PCR confirmed
the absence of Ccl2 in gene-deficient cultures.
Astrocyte stimulation
16 hours prior to stimulation, cultures were washed in
HBSS and cultured with low-serum medium (DMEM
containing 1% FBS). Astrocytes were then stimulated
with either LPS (from Escherichia coli 0111:B4 g-irra-
diated; 0.1-100 μg/ml), mouse recombinant (r) IL-1b (<1
EU/μg endotoxin; Peprotech, Rocky Hill, NJ; 0.1-50 ng/
ml) or rCCL2 (R&D Systems, Minneapolis, MN; 50-500
ng/ml) in low-serum (1%) DMEM. LPS and IL-1b in par-
ticular have been shown to induce cytokine production
by cultured astrocytes across a wide range of concentra-
tions, from 1 ng/ml to 1 mg/ml LPS [21-30] and between
0.1 - 100 ng/ml IL-1b [31-35]. In some experiments, cul-
tures were pre-treated with rCCL2 (250 ng/ml) for 12 h,
before the addition of LPS or IL-1b for a further 8 h.
This experimental design was based on one previously
used to demonstrate the regulation of macrophage cyto-
kine production by the chemokine fractalkine [36]. Three
separate cultures were stimulated, such that data repre-
sents the mean of three independent experiments. Paral-
lel astrocyte cultures were incubated in medium alone as
unstimulated controls. After stimulation (2 - 48 h) super-
natant was collected, centrifuged (1000 rpm, 10 min at 4°
C) and stored at -20°C until analysis, whilst cells were
washed in HBSS and scrapped for collection, then centri-
fuged prior to storage of cell pellets at -80°C.
Measurement of cytokine production in culture
supernatants
Commercially-available mouse multiplex kits (LINCO-
plex; Millipore, Billerica, MA) were used to quantify the
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chemokines CXCL1, CCL3 and CCL5, in culture super-
natants following stimulation with LPS. These five
inflammatory mediators are all reportedly produced by
mouse, rat and human astrocytes, in response to a vari-
ety of stimuli including mechanical injury and pro-
inflammatory cytokines. Mouse IL-6 secreted in
response to IL-1b stimulation was measured using
Quantikine Immunoassays (R&D Systems; lower detec-
tion limit <1.6 pg/ml).
Quantification of gene expression by real-time reverse
transcriptase polymerase chain reaction (qPCR)
RNA was extracted and isolated from astrocyte cells
using the Purelink RNA Mini Kit (Invitrogen), including
on-column DNase treatment, as per the manufacturers’
instructions. RNA concentration and purity was deter-
mined using a Nanodrop1000 spectrophotometer
(Thermo Fisher Scientific), with an absorbance ratio at
260 and 280 nm of >1.9 considered as highly pure RNA.
One microgram of each sample was reverse transcribed
into complementary-strand DNA (cDNA) using Super-
Script™ III reverse transcriptase and oligo d(T)20 as the
primer according to the manufacturers’ protocol (Invi-
trogen). Quantitative PCR (qPCR) was performed using
the TaqMan Universal master mix (Applied Biosystems,
Foster City, CA) and TaqMan® gene expression assay for
mouse IL-6 (Mm01210733_m1, Applied Biosystems).
Samples were assayed in triplicate on a 384 well plate
using the 7900 Fast Real-Time PCR system (Applied
Biosystems).
The widely-accepted comparative Ct (threshold cycle)
method was used to perform relative quantification of
qPCR results [37]. An arithmetic formula (fold differ-
ence = 2
-ΔΔCt) was used to calculate the relative mRNA
expression of stimulated cultures compared to unstimu-
lated controls, after normalisation to levels of the house-
keeping control gene, glyceraldehyde-3-phosphate
dehydrogenase (GAPDH; Mm99999915_g1). Data are
thus expressed as fold change compared to unstimulated
wild-type cells.
Statistical analysis
Statistical analysis was performed using Sigma Stat 2.03
software (SPSS Inc., Chicago, IL). Data shown represent
means ± standard error of the mean (SEM) from at
least three independent experiments. Two-way Analysis
of Variance (ANOVA) tests were used to evaluate cyto-
kine production across time or different stimulus con-
centrations, with overall significance for factors of strain
and time/concentration reported as such. Tukey’st e s t
was employed for post-hoc comparisons between and
within individual factors (indicated on figures by * and #),
whilst differences between two factors (e.g. gene
expression in LPS-stimulated wild-type and Ccl2-/- cells)
were analysed by t-tests. When necessary, non-para-
metric data was normalised by transformation by natural
log (ln) prior to statistical analysis. Statistical significance
was considered at the 5% level (p < 0.05).
Results
Cytokine production was exacerbated in LPS-stimulated
Ccl2-/- astrocytes
Concentration of several cytokines and chemokines were
measured in supernatant collected from wild-type and
Ccl2-/- astrocyte cultures, to determine the effect of
Ccl2 gene deletion on the inflammatory response to LPS
stimulation. From preliminary experiments examining a
time-course of LPS stimulation (range of 1 - 48 h), we
determined that sub-maximal cytokine production was
evident by 8 h (data not shown). Thus the concentration
of IL-6, TNF, CXCL1 (KC), CCL3 (MIP-1a)a n dC C L 5
(RANTES) was measured after 8 h of LPS exposure. As
expected, cytokine production was at low or undetect-
able levels in unstimulated astrocyte cultures (0 μg/ml
LPS) in both cell genotypes (figure 1).
In general, the cytokines IL-6 and TNF (figure 1a and
1b) were differentially stimulated in Ccl2-/- astrocytes
across the range of LPS concentrations (0.1 - 100 μg),
with exacerbated production compared to wild-type
cells. For IL-6, no differences were noted between the
strains at 0.1 μg/ml LPS, whereas from 1-100 μg/ml,
whilst IL-6 production by wild-type cells reached a pla-
teau, production by Ccl2-/- astrocytes increased dose-
dependently (p < 0.01; 2-way ANOVA effect of strain).
TNF secretion showed a similar pattern, with Ccl2-/-
astrocytes showing significantly greater cytokine produc-
tion from 0.1 μg/ml LPS onwards (p < 0.001; 2-way
ANOVA effect of strain). In addition, production of the
neutrophil chemoattractant CXCL1 (figure 1c) and two
macrophage chemokines CCL3 and CCL5 (figure 1d
and 1e) was significantly elevated in Ccl2-/- astrocytes
(p < 0.01; 2-way ANOVA effect of strain), with the later
being particularly exacerbated in gene-deficient cells at
higher LPS concentrations of 10 and 100 μg/ml (p <
0.001; post-hoc). CCL5 was secreted at notably lower
levels (~ 5-15 pg/ml) compared to CCL3 and CXCL1
(~ 100-400 pg/ml) in cell supernatant, however its con-
centration was consistently enhanced in Ccl2-/- com-
pared to wild-type astrocytes ((p < 0.01; 2-way ANOVA
effect of strain).
Importantly, whilst cytokine and chemokine produc-
tion was induced in wild-type cells by LPS treatment,
this effect appeared to plateau from 0.1 μg/ml LPS, after
which increasing concentrations of the stimulus did not
augment mediator secretion further. In contrast, Ccl2-/-
astrocytes exhibited an increasing dose-dependent
response, with the maximal LPS concentration used
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Page 3 of 11Figure 1 Exacerbated cytokine production in Ccl2-/- astrocyte supernatant in response to LPS. Levels of inflammatory mediators were
measured by multiplex assay in astrocyte supernatants following incubation for 8 h with LPS (0-100 μg/ml). Production of IL-6 and TNF (a and
b), as well as the chemokines CXCL1, CCL3 and CCL5 (c, d and e), was increased in response to LPS stimulation (p < 0.001, 2-way ANOVA effect
of concentration), and was exacerbated in Ccl2-/- astrocyte cultures compared to wild-type (p < 0.01; 2-way ANOVA effect of strain). The hash
symbol (#) represents post-hoc analysis of differences between cytokine/chemokine levels at increasing LPS concentrations (# p < 0.05; ## p <
0.01), whilst stars (*) annotate post-hoc analysis of differences between strains (* p < 0.05; ** p < 0.01; *** p < 0.001). Data represent mean +
sem of three separate experiments assayed in duplicate. Spnt = supernatant.
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mediators (p < 0.001, 2-way ANOVA effect of
concentration).
IL-6 is a pleiotropic cytokine with diverse roles in the
injured CNS [38]. Both in the injured brain and in sti-
mulated astrocyte cultures, IL-6 is produced at high
concentrations as compared to other mediators
[9,22,26,31,39]. Furthermore, glial-derived IL-6 is pivotal
in multiple neuroinflammatory cascades, as Il-6-gene
deficient astrocytes in vitro show an altered cytokine
profile compared to wild-type control cultures [23].
Therefore, subsequent experiments focused on IL-6 pro-
duction to enable better detection of selective responses
resulting from stimulation with LPS or IL-1b.T h ed i f -
ferential production of IL-6 by Ccl2-/- astrocytes was
thus also examined at the transcriptional level, by quan-
tifying gene expression in stimulated cells by qPCR
(figure 2). Whilst minimal IL-6 was detectable in unsti-
mulated cells from either strain, following incubation
with LPS (1 μg/ml), IL-6 mRNA levels were increased
125-fold in wild-type astrocytes. Furthermore, IL-6
expression in Ccl2-/- astrocytes was significantly
enhanced, with an additional upregulation of approxi-
mately 50% compared to wild-type cells (p < 0.05).
IL-6 production by IL-1b-stimulated Ccl2-/- astrocytes is
concentration-dependent
Astrocyte cultures were next treated with the pro-
inflammatory cytokine IL-1b, to determine whether the
differential response of Ccl2-/- cells to LPS could also
be induced by a milder stimulus with close relevance to
post-traumatic neuroinflammation [40,41]. Measurement
of IL-6 in the supernatant surprisingly revealed lower
levels of IL-6 produced by Ccl2-/- astrocytes compared
to wild-type cells after 8 h exposure to 1 ng/ml IL-1b
(p < 0.001; post-hoc). Inversely, when using higher con-
centrations of IL-1b (10 or 50 ng/ml), a greater response
was detected in Ccl2-/- astrocytes compared to that
observed in wild-type cells (p < 0.001 and p < 0.01
respectively; post-hoc) (figure 3a).
To further investigate this incongruity, wild-type and
Ccl2-/- astrocyte cultures were treated with IL-1b at 1,
10 or 50 ng/ml and compared across a time course of
2-2 4h .I L - 1 b at 1 ng/ml simulated low levels of IL-6
by astrocytes from both strains (< 7 pg/ml in wild-type
cultures and < 2 pg/ml in Ccl2-/- cultures), with IL-6
secretion being consistently higher (~2-8 pg/ml) in wild-
type astrocytes compared to Ccl2-/- cells (<2 pg/ml; p <
0.001; 2-way ANOVA effect of strain), which was evi-
dent at all time points from 2 h onwards (p < 0.001;
post-hoc) (figure 3b). In contrast, using a higher concen-
tration of IL-1b (10 ng/ml) induced a greater production
of IL-6 compared to 1 ng/ml stimulation in both strains.
IL-6 secretion was increased in wild-type astrocytes at
4 h compared to 2 h, however, little additional secretion
was seen with an increased length of exposure (4-24 h)
(figure 3c). On the contrary, IL-6 induction in Ccl2-/-
astrocytes was more robust across the time course, with
production exacerbated above levels in wild-type astro-
cytes steadily increasing over time to a maximum after
24 h stimulation (p < 0.001; post-hoc).
Similarly, stimulation with IL-1b at 50 ng/ml induced
a further enhanced response from Ccl2-/- astrocytes
compared to wild-type (2-way ANOVA effect of strain).
This was evident as early as 2 h (6.32 ± 0.57 pg/ml; p <
0.01, post-hoc) and maintained across the time course,
with IL-6 secretion peaking in Ccl2-/- astrocytes at 24 h
(33.74 ± 2.24 pg/ml) (figure 3d). Interestingly, differ-
ences between the strains were less pronounced at
50 ng/ml compared to IL-6 production induced by
IL-1b at 10 ng/ml.
In summary, the enhanced production of IL-6 in
Ccl2-/- astrocytes following IL-1b stimulation was
dependent on the concentration of the stimulus, but
independent of the length of exposure time.
Exogenous CCL2 does not induce cytokine release in
astrocytes
Given the differential production of cytokines in the
absence of CCL2, we postulated that treatment with the
exogenous recombinant chemokine may modulate cyto-
kine secretion.
To ascertain this hypothesis, wild-type cultures were
incubated with mouse rCCL2 for 12 h with a range of
concentrations (50, 100, 250 and 500 ng/ml), and the
production of IL-6, TNF, CXCL1, CCL3 and CCL5 was
measured in the collected supernatant. Even at the
Figure 2 IL-6 mRNA expression is exacerbated in Ccl2-/-
astrocytes following LPS stimulation. Expression of IL-6 mRNA
was measured by qPCR in cell lysates following stimulation with
1 μg/ml LPS for 8 h. Whilst mRNA levels were minimal in
unstimulated cells, IL-6 expression was strongly induced by LPS
exposure in astrocytes from both strains (# p < 0.001; 2-way ANOVA
effect of treatment). Furthermore, significantly higher expression of
IL-6 mRNA was detected in Ccl2-/- astrocytes after LPS treatment
compared to LPS-treated wild-type cells (* p < 0.05). Data represent
mean + sem of three separate experiments assayed in triplicate.
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CXCL1, CCL3 and CCL5 were below detectable levels
(reported as 0.9, 1.2, 2.8 and 0.7 pg/ml respectively). IL-
6 concentrations were barely detectable in unstimulated
cultures, and increasing concentrations of rCCL2 had
no additional effect on IL-6 secretion (p = 0.700; one-
w a yA N O V A ;d a t an o ts h o w n ) .S i m i l a r l y ,I L - 6p r o d u c -
tion from Ccl2-/- astrocytes following rCCL2 treatment
was negligible (<0.2 pg/ml; data not shown).
rCCL2 reduces IL-1b induction of IL-6 production and
expression
Since IL-1b stimulated a differential IL-6 production in
wild-type and Ccl2-/- astrocytes, we hypothesised that
pre-treatment with rCCL2 prior to exposure to IL-1b
may attenuate this cytokine response. Therefore, cul-
tures from wild-type mice were firstly incubated for 12
h with either media only or rCCL2 (250 ng/ml; 8 h),
before the addition of IL-1b (10 or 50 ng/ml) as the sti-
mulus. As expected, IL-6 measured in the supernatant
of wild-type cultures was increased following stimulation
with IL-1b at both 10 and 50 ng/ml (p < 0.01; 2-way
ANOVA effect of concentration). Importantly, rCCL2
pre-treatment significantlyr e d u c e dI L - 6p r o d u c t i o n
induced by IL-1b compared to pre-treatment with
media only. This was most notably at 10 ng/ml, whereby
~ 50% less IL-6 was detected in supernatant from
rCCL2-treated cultures (p < 0.01; post-hoc; figure 4a).
IL-6 gene expression was next measured by qPCR in
wild-type cells collected post-stimulation (figure 4b). As
for supernatant measurements, cultures were incubated
for 12 h with either media only or rCCL2 (250 ng/ml),
before the addition of IL-1b (10 ng/ml; 8 h). 10 ng/ml of
IL-1b was chosen for investigation, as it was the
Figure 3 IL-6 production by IL-1b-stimulated astrocytes is concentration-dependent and enhanced in Ccl2-/- cells. IL-6 levels were
measured in astrocyte supernatant following stimulation with IL-1b at various concentrations (a) and time periods (b-d). At 1 ng/ml IL-1b, wild-
type cells produced significantly more IL-6 compared to Ccl2-/- astrocytes from 2-24 h exposure, albeit at low levels. In contrast, at 10 and 50
ng/ml IL-1b, Ccl2-/- astrocytes produced significantly higher levels of IL-6 across the time course. Stars annotate p-values representing differences
between strains from post-hoc analysis (*p < 0.05; **p < 0.01; ***p < 0.001), whilst the hash symbol designates differences between stimulation
times/concentrations (# p < 0.001). Data represent mean + sem of three separate experiments assayed in duplicate. Spnt = supernatant.
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rCCL2 inhibition (figure 4a). Consistent with protein
production, the levels of IL-6 mRNA were consistently
low in unstimulated cells regardless of pre-incubation
with either media alone or rCCL2. Also consistent with
the protein data, IL-1b stimulation robustly increased
IL-6 expression by ~ 50 fold compared to levels in
unstimulated cells (p < 0.001; 2-way ANOVA). In con-
trast, rCCL2 pre-treatment significantly inhibited IL-6
mRNA levels in response to IL-1b by 44% compared to
pre-treatment with media alone (p < 0.05), correspond-
ing with the reduced IL-6 protein detected under the
same conditions.
Discussion
Investigations into inflammatory neuropathologies such
as multiple sclerosis and stroke have demonstrated
neuroprotection resulting either from interference with
the Ccl2 gene, by administration of neutralising anti-
CCL2 antibodies, or targeting the CCR2 receptor
[7,42-44]. Besides the chemotactic ability of CCL2 to
drive the migration of monocytic cells into the brain,
recent evidence has shown that CCL2 also has alterna-
tive neuroactive properties in the CNS [17-19,45].
Furthermore, research by our group and others have
reported alterations in the inflammatory cytokine
response and tissue damage in Ccl2-deficient mice after
TBI or stroke, prior to the onset of leukocyte infiltration
[7,9]. The purpose of our current study was thus to
investigate whether CCL2 can influence astrocyte-speci-
fic cytokine secretion following an immune challenge
in vitro.
The production of the cytokine IL-6 and chemokines
CXCL1 and CCL3 was significantly exacerbated in the
supernatant of Ccl2-/- astrocytes following stimulation
with LPS, corresponding to the delayed and enhanced
secretion detected in the injured mouse brain [9]. TNF,
whose production was elevated in the brains of Ccl2-/-
mice across a time course of 2-24 h after experimental
TBI, was also elevated in LPS-stimulated Ccl2-/- astro-
cytes in vitro. Differences in cytokine protein levels in
wild-type and Ccl2-/- astrocyte cultures are likely due to
variations in gene expression, as we also detected an
enhanced elevation of IL-6 mRNA levels in Ccl2-/-
astrocytes compared to wild-type cells.
Interestingly, the macrophage chemoattractant CCL5
was produced at lower levels in the brains of Ccl2-/-
mice compared to wild-type after TBI, however, gene-
deficient astrocytes had a profile of exacerbated CCL5
production. Particularly considering the low concentra-
tion of CCL5 detected in culture supernatant following
LPS stimulation compared to the other cytokines mea-
sured, it is possible that this chemokine may be primar-
ily produced during neuroinflammation by other CNS
cells such as microglia, as has been previously suggested
[35,46,47].
For subsequent experiments we focused specifically on
astrocyte production of IL-6, as this multi-functional
cytokine is central to CNS inflammation and degenera-
tion following TBI [40,41], and is secreted in vitro in
response to mechanical injury and exposure to inflam-
matory cytokines [22,26,29,31,48,49]. Consistent with
the LPS-stimulated phenotype, a similarly enhanced
response by Ccl2-/- astrocytes was evident following sti-
mulation with the pro-inflammatory cytokine IL-1b at
both 10 and 50 ng/ml. Interestingly, this characteristic
exacerbated response was not evident in Ccl2-/- astro-
cytes at a lower concentration of IL-1b (1 ng/ml), when
wild-type cells produced a higher level of IL-6. This
finding may reflect what we observed in vivo,w h e r e
secretion of IL-6 was similar in wild-type and Ccl2-/-
Figure 4 Pre-treatment with rCCL2 inhibits IL-1b induction of
IL-6. Wild-type astrocytes were firstly pre-incubated with rCCL2
(250 ng/ml) or media only for 12 h before the addition of IL-1b (10 or
50 ng/ml) for a further 8 h. IL-6 protein secretion in supernatant was
detected by ELISA (a) and mRNA levels were measured in cell lysates
by qPCR (b). IL-6 protein production increased in response to IL-1b
stimulation (# p < 0.01; 2-way ANOVA). Pre-treatment with rCCL2
effectively reduced IL-6 production induced by IL-1b at 10 ng/ml
(** p < 0.01). IL-6 mRNA was similarly increased after incubation with
IL-1b (## p < 0.001; 2-way ANOVA). This response was reduced by
pre-treatment with rCCL2 (* p < 0.05). Data represent mean + sem of
three separate experiments assayed in triplicate.
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enhanced response in Ccl2-/- mice occurred at 12 h,
corresponding to the time of maximal IL-1b in the
lesioned cortex [9].
There have been several other studies suggesting that
Ccl2-deficiency deregulates inflammatory cytokine synth-
esis in the CNS, primarily restricted to in vivo rodent
models. Contrary to our findings, Hughes and colleagues
(2006) reported that IL-6 and IL-1b were significantly
reduced in the brains of Ccl2-/- mice after induction of
ischaemic stroke [7]. Similarly, lower levels of IL-1b and
TNF were induced in Ccl2-/- mice compared to wild-type
after a striatal injection of LPS [50]. A third study also
using LPS as the stimulus found that peripheral adminis-
tration resulted in elevated IL-1b and TNF levels in serum
of Ccl2-/- mice, whereas cytokine production in the brain
was attenuated [51]. It is worth noting that all three of
these studies considered only one time point (6 h) after
stroke or LPS stimulation. Since we have shown here that
alterations in cytokine production resulting from Ccl2-
deficiency are time and concentration-dependent both
in vivo and in vitro, it is possible that these studies do not
comprehensively reflect the overall neuroinflammatory
response specific to this strain. Importantly, our current
work is the first to examine Ccl2-deficient anomalies in
cytokine production or synthesis in depth by using an
in vitro system of astrocyte activation.
Previous studies have suggested that the early and
robust upregulation of CCL2 in neuropathologies such
as TBI may indicate a central role for this chemokine in
initiating the cytokine response [7]. Given that cytokine
production in the brain coincides with CCL2 upregula-
tion and most often precedes evidence of microglial
activation or macrophage infiltration from the periphery,
it is unlikely that the influence of CCL2 on acute cyto-
kine production is dependent on the chemoattraction of
leukocytes and subsequent secretion from these cells
[51]. Furthermore, investigation of the macrophage and
microglial marker F4/80 in the brains of Ccl2-/- mice
early after injury or disease onset has failed to detect
any difference from wild-type mice, suggesting that the
contribution of CCL2 to acute neuropathology may be
independent to its classic actions as a chemokine
[7,50,52]. Given that incubation of cultured astrocytes
with rCCL2 alone does not induce production of IL-6,
TNF, CXCL1, CCL3 or CCL5 above levels in unstimu-
lated cells, it is also unlikely that CCL2 directly stimu-
lates cytokine production from astrocytes.
Alternatively, based on our findings of exacerbated
cytokine production in the brains of injured Ccl2-deficient
mice and immune-challenged Ccl2-deficient astrocytes, we
hypothesised that CCL2 may act during early immunoacti-
vation in an inhibitory manner. Interestingly, CCL2 has
recently been proposed to protect neurons from cell death
induced by N-methyl-D-aspartate, glutamate, b-amyloid
and human immunodeficiency virus-mediated Tat toxicity
[17-19]. Further prompting our own investigations into
alternative properties of CCL2, Rankine and colleagues
(2006) previously showed that co-administration of LPS
and rCCL2 into the mouse brain did not have a synergistic
pro-inflammatory effect as they had hypothesised -
instead, the addition of rCCL2 in combination with LPS
resulted in a non-significant trend towards reduced IL-6
production.
Also relevant to our findings, Zisman and colleagues
showed that treatment with anti-CCL2 antibodies prior
to an intraperitoneal LPS challenge increased plasma
TNF and IL-12 levels, whilst administration of rCCL2
reduced pro-inflammatory cytokine production by
20-35% [53]. Similarly, in cultured astrocytes we have
demonstrated that pre-exposure to rCCL2 was sufficient
to reduce the IL-1b-stimulated production of IL-6 in cul-
ture supernatant. Furthermore, this inhibitory effect was
also evident at a transcriptional level, as the increase in
IL-6 mRNA expression induced by IL-1b stimulation was
significantly lower in rCCL2-treated cultures. To our
knowledge, this is the first in vitro evidence that CCL2
can act on astrocytes in an immunomodulatory manner
to down-regulate cytokine expression and production.
One limitation of this study is the relative simplicity of
the culture system used. It must be noted that cultured
primary astrocytes may respond quite differently in iso-
lation compared to in vivo, where they may be influ-
enced by interactions with adjacent endothelial cells,
microglia and extracellular matrix components. How-
ever, the consistency between our findings in cultured
astrocytes and the mouse cortex in vivo [9] supports the
use of primary astrocyte cultures as an appropriate
model system.
The mechanisms underlying a novel role for CCL2 in
CNS cytokine production need to be further elucidated.
Whilst CCL2 mediates immune cell chemotaxis by bind-
ing to the CCR2 receptor, the presence of CCR2 on
astrocytes in the brain remains controversial [14,54-57].
Quinones and colleagues recently found that CCL2
treatment in vitro can induce glial cell migration and
inhibit the spontaneous apoptosis of mouse astrocytes in
a dose-dependent manner. Whilst the latter pro-survival
effect was shown to be dependent on signaling via
CCR2, residual chemotaxis of Ccr2-/- astrocytes in
response to CCL2 may indicate the presence of an alter-
native receptor for this chemokine on primary astrocytes
[58]. Whether CCR2 is the primary receptor involved in
CCL2-modulation of cytokine production, and which
intracellular pathways are responsible for the reduction
in cytokine expression observed in IL-1b-stimulated
astrocytes pre-exposed to rCCL2, remain unanswered.
The use of specific neutralising antibodies, or the
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in which gene deletion is specific to either astrocytes or
endothelial cells, may prove essential in answering these
questions and eliminating potential confound resulting
from global gene deficiency [59].
Lastly, the consequences of an altered cytokine envir-
onment in the presence or absence of CCL2 remain
unclear. Of note, Ccl2-/- mice show long-term improve-
ments in neurological recovery and reduced tissue
damage following experimental TBI, despite the aberra-
tions in early cytokine secretion [9]. Given the acute nature
of cytokine production in the injured brain, it is feasible
that the aberrant, exacerbated cytokine profile seen in
Ccl2-/- mice may contribute to early post-traumatic
degeneration in this strain, which may compensate for
the lack of CCL2 and contribute to early leukocyte infil-
tration. We hypothesise that CCL2 may have differential
acute and long-term effects during neuropathology, as
has been indicated for TNF [60,61]. A deeper under-
standing of the consequences of CCL2 deletion in CNS
inflammation and cytokine production may allow us to
better tailor therapeutic approaches to the appropriate
time post-injury. Thus further studies are necessary to
elucidate the biological and physiological relevance of
these findings.
Conclusions
I nt h ec u r r e n ts t u d yw eh a v ee m p l o y e da nin vitro
model of astrocyte activation to characterise the Ccl2-/-
genotype-specific profile of cytokine and chemokine
secretion as observed in the injured brains of Ccl2-/-
mice. Our findings provide evidence that astrocytes are
primarily responsible for exacerbated cytokine response
in the absence of CCL2. Furthermore, we present data
showing that rCCL2 can inhibit the astrocytic produc-
tion of inflammatory cytokines in response to IL-1b sti-
mulation. In light of these findings, we propose that
CCL2 plays a novel, immunomodulatory role in the
inflamed CNS by altering cytokine production in astro-
cytes, and that this effect is relative to the concentration
of the stimulus present. This study highlights the com-
plexity of chemokine - cytokine interactions in the CNS,
and suggests that CCL2 may affect multiple cytokine
pathways which could participate in neurodegenerative
processes. Our data indicate that chemoattraction of
immune cells is only one of the functions performed by
CCL2 in the injured CNS, and that further investigation
is required before targeting of this chemokine as a
means of neuroprotection for neuropathologies in which
CCL2 upregulation is a characteristic feature.
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